PE20240797A1 - Composiciones farmaceuticas de un anticuerpo contra pd-1 y uso de las mismas - Google Patents
Composiciones farmaceuticas de un anticuerpo contra pd-1 y uso de las mismasInfo
- Publication number
- PE20240797A1 PE20240797A1 PE2024000052A PE2024000052A PE20240797A1 PE 20240797 A1 PE20240797 A1 PE 20240797A1 PE 2024000052 A PE2024000052 A PE 2024000052A PE 2024000052 A PE2024000052 A PE 2024000052A PE 20240797 A1 PE20240797 A1 PE 20240797A1
- Authority
- PE
- Peru
- Prior art keywords
- antibody against
- pharmaceutical compositions
- approximately
- pharmaceutical composition
- cancer
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 1
- 208000037540 Alveolar soft tissue sarcoma Diseases 0.000 abstract 1
- 102000008096 B7-H1 Antigen Human genes 0.000 abstract 1
- 108010074708 B7-H1 Antigen Proteins 0.000 abstract 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract 1
- 229930006000 Sucrose Natural products 0.000 abstract 1
- 201000005188 adrenal gland cancer Diseases 0.000 abstract 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 abstract 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 abstract 1
- 229920000053 polysorbate 80 Polymers 0.000 abstract 1
- 229940068968 polysorbate 80 Drugs 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 229940018007 retifanlimab Drugs 0.000 abstract 1
- 239000005720 sucrose Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Referido a una composicion farmaceutica que comprende anticuerpo contra PD-1 y agentes reguladores de pH: a) aproximadamente de 10 mg/ml a aproximadamente 100 mg/ml de retifanlimab, b) acetato, c) sacarosa, d) polisorbato 80 ("PS80"), y e) agua. Tambien se refiere a recipientes y kit que comprende dicha composicion farmaceutica y su uso para tratar el cancer que expresa PD-L1, tales como cancer de glandula suprarrenal, cancer asociado al SIDA, sarcoma alveolar de partes blandas, entre otros.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163220006P | 2021-07-09 | 2021-07-09 | |
| PCT/US2022/034493 WO2023283049A1 (en) | 2021-07-09 | 2022-06-22 | Pharmaceutical compositions of a pd-1 antibody and use of the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20240797A1 true PE20240797A1 (es) | 2024-04-18 |
Family
ID=82608118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2024000052A PE20240797A1 (es) | 2021-07-09 | 2022-06-22 | Composiciones farmaceuticas de un anticuerpo contra pd-1 y uso de las mismas |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230025464A1 (es) |
| EP (1) | EP4366692A1 (es) |
| KR (1) | KR20240035533A (es) |
| CN (1) | CN118215465A (es) |
| AR (1) | AR126404A1 (es) |
| AU (1) | AU2022307332A1 (es) |
| CA (1) | CA3224640A1 (es) |
| CO (1) | CO2024000198A2 (es) |
| IL (1) | IL309985A (es) |
| PE (1) | PE20240797A1 (es) |
| TW (1) | TW202308694A (es) |
| WO (1) | WO2023283049A1 (es) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4007602A1 (en) * | 2019-08-01 | 2022-06-08 | Incyte Corporation | A dosing regimen for an ido inhibitor |
| US20220283167A1 (en) * | 2019-08-05 | 2022-09-08 | Ono Pharmaceutical Co., Ltd. | Biomarkers for determining the efficacy of immune checkpoint inhibitors |
-
2022
- 2022-06-22 PE PE2024000052A patent/PE20240797A1/es unknown
- 2022-06-22 CA CA3224640A patent/CA3224640A1/en active Pending
- 2022-06-22 EP EP22744039.3A patent/EP4366692A1/en active Pending
- 2022-06-22 KR KR1020247004643A patent/KR20240035533A/ko unknown
- 2022-06-22 IL IL309985A patent/IL309985A/en unknown
- 2022-06-22 AU AU2022307332A patent/AU2022307332A1/en active Pending
- 2022-06-22 CN CN202280059325.XA patent/CN118215465A/zh active Pending
- 2022-06-22 US US17/847,094 patent/US20230025464A1/en active Pending
- 2022-06-22 WO PCT/US2022/034493 patent/WO2023283049A1/en active Application Filing
- 2022-07-05 TW TW111125067A patent/TW202308694A/zh unknown
- 2022-07-07 AR ARP220101785A patent/AR126404A1/es unknown
-
2024
- 2024-01-11 CO CONC2024/0000198A patent/CO2024000198A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202308694A (zh) | 2023-03-01 |
| US20230025464A1 (en) | 2023-01-26 |
| CO2024000198A2 (es) | 2024-02-05 |
| AU2022307332A1 (en) | 2024-01-18 |
| AR126404A1 (es) | 2023-10-11 |
| EP4366692A1 (en) | 2024-05-15 |
| KR20240035533A (ko) | 2024-03-15 |
| CN118215465A (zh) | 2024-06-18 |
| IL309985A (en) | 2024-03-01 |
| CA3224640A1 (en) | 2023-01-12 |
| WO2023283049A1 (en) | 2023-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20131324A1 (es) | Formulacion subcutanea de anticuerpo anti-her2 | |
| CL2021001292A1 (es) | Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres | |
| DOP2022000115A (es) | Tetrahidrofuranos sustituidos como moduladores de canales de sodio | |
| AR063201A1 (es) | Composiciones farmaceuticas de ropinirol y metodos de uso de las mismas | |
| CL2020000468A1 (es) | Uso de una formulación estable que comprende una enzima de reemplazo para la enzima lisosomal (divisional solicitud 201801220) | |
| PE20190469A1 (es) | Formulaciones, kits y metodos de anticuerpos inhibidores de masp-2 de baja viscosidad altamente concentrados | |
| MA45280B1 (fr) | Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation | |
| PE20190761A1 (es) | Inhibidores de procesos metabolicos celulares | |
| IN2015MU00865A (es) | ||
| CL2018003604A1 (es) | Composiciones farmacéuticas para terapia combinada (divisional solicitud 201701983) | |
| AR054805A1 (es) | Composiciones topicas para el tratamiento de la piel | |
| CO2020014217A2 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos | |
| PE20061043A1 (es) | Composicion farmaceutica que comprende anticuerpos monoclonales | |
| CL2013003163A1 (es) | Composición transdermica de ibuprofeno, util en el tratamiento del dolor o la inflamacion. | |
| MA40768A (fr) | Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue | |
| EA202190471A1 (ru) | Комбинация конъюгата антитела-лекарственного средства и ингибитора тубулина | |
| BR112022001897A2 (pt) | Composições de higiene pessoal | |
| CO2021010493A2 (es) | Compuestos de halo-alilamina y uso de los mismos | |
| CO6280488A2 (es) | Combinacion farmaceutica | |
| BR112023023463A2 (pt) | Inibidores da interação menin-mll | |
| PE20240797A1 (es) | Composiciones farmaceuticas de un anticuerpo contra pd-1 y uso de las mismas | |
| CO2022014499A2 (es) | Moduladores de nlrp3 | |
| AR090244A1 (es) | Formulacion de anticuerpo anti-selectina p | |
| CO2023014204A2 (es) | Inhibidores de la cinasa relacionada con el gen nunca en mitosis a 7 (nek7) | |
| PE20220250A1 (es) | Uso de docetaxel en el tratamiento de cancer mediante control de niveles maximos en plasma |